Corona Remedies Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹342Cr
- +14.8% YoY
- −5.3% QoQ
- Net profit
- ₹41Cr
- −8.9% YoY
- −21.2% QoQ
- Margin
- 24%
- +1 pp YoY
- +2 pp QoQ
Guidance rank: #51 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
CORONA Remedies targets a consistent revenue growth of around 15% annually, outpacing the Indian Pharmaceutical Market (IPM). CORONA Remedies targets consistent mid-teen revenue growth (~15%) and high-teen PAT growth (~20%) annually.
From Corona Remedies Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- CORONA Remedies targets a consistent revenue growth of around 15% annually, outpacing the Indian Pharmaceutical Market (IPM).
- PAT (Profit After Tax) growth expectation is high-teens to 20% annually.
- Volume growth contributes approximately 5% to overall growth, supported by new product introductions.
- The company plans to launch 8 to 10 new products yearly, primarily organically (95%), with a few acquisitions (5-7%).
- Expansion includes entry into new therapies like infertility, rheumatology, and spine.
- Growth is driven by chronic and semi-chronic segments, constituting around 70-72% of revenue.
- Increasing market share through specialist and super-specialist prescribers is a key focus.
2 more points from Corona Remedies Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Corona Remedies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Recently capitalized a 600 kg manufacturing line, unlocking 40% capacity.
- Planning to consider adding a new manufacturing block around FY'28-'29 to support future growth.
- Currently, no immediate need to add new lines such as injectable or biosimilar lines; will evaluate at the appropriate time.
- Maintain a balanced mix of 65% in-house manufacturing and 35% CDMO/CMO outsourcing.
2 more points from Corona Remedies Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Corona Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Corona Remedies Ltd's call on order book
Create a free account to keep reading this call
Corona Remedies Ltd — Quarterly revenue & net profit
Corona Remedies Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 342 | 298 | +14.8% | 361 | -5.3% |
| Operating profit (EBITDA) | 83 | 69 | +20.3% | 78 | +6.4% |
| Operating margin | 24% | 23% | +1 pp | 22% | +2 pp |
| Profit before tax | 55 | 58 | -5.2% | 70 | -21.4% |
| Net profit (PAT) | 41 | 45 | -8.9% | 52 | -21.2% |
| EPS (₹) | 6.74 | 7.32 | -7.9% | 8.53 | -21% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹441 Cr, net profit ₹60 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Corona Remedies's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Corona Remedies Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Corona Remedies Ltd Q3 FY26 results?
CORONA Remedies targets a consistent revenue growth of around 15% annually, outpacing the Indian Pharmaceutical Market (IPM). CORONA Remedies targets consistent mid-teen revenue growth (~15%) and high-teen PAT growth (~20%) annually.
What is Corona Remedies Ltd share price analysis?
Corona Remedies Ltd currently shows a neutral. The stock trades at a P/E of 60.6 with a market cap of ₹12,823 Cr. Investors should review the full earnings analysis for detailed insights.
Is Corona Remedies Ltd planning capital expenditure?
Recently capitalized a 600 kg manufacturing line, unlocking 40% capacity.
Keep Corona Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
